Navigation Links
Caris Life Sciences Announces Presentations at ESMO 2017 Highlighting Ability of Its Tumor Molecular Profiling to Develop Therapeutic Strategies
Date:9/7/2017

IRVING, Texas, Sept. 7, 2017 /PRNewswire/ -- Caris Life Sciences, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced results from two studies that further validate the benefits of its molecular profiling approach in guiding therapeutic strategies in oncology.  Each study utilized comprehensive genomic profiling plus (CGP+) with Caris Molecular Intelligence® to stratify each individual patient's tumor on a molecular level, leading to more therapeutic options and improved outcomes.  The data will be presented in two poster presentations at the European Society of Medical Oncology (ESMO) Conference on September 8 – 12, 2017, in Madrid, Spain.

"By identifying the molecular profile of malignant cells, we are enabling the identification of a treatment path that better targets what is causing malignant disease and thus results in better treatment selection and ultimately better patient outcomes," said David Spetzler, M.S., Ph.D., M.B.A., President and Chief Scientific Officer of Caris Life Sciences. "These studies provide further evidence that molecular profiling is a productive approach to assist clinicians in developing a therapeutic path for their patients, particularly in very challenging patients as included in these analyses."

Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune check-point blockade therapy
Poster Display Session
Poster: 100P, Hall 8
September 9, 1:15 – 2:15 p.m. CEDT

Summary: Carcinoma of unknown primary ?CUP? tissue accounts for approximately 3% of all malignancies. 389 cases with CUP were evaluated by Next-Generation Sequencing (592 DNA genes and 53 RNA genes) for point mutations, copy number variations, insertions/deletions, fusions, tumor mutational load (TML) and microsatellite instability (MSI), as well as Immunohistochemistry for PD-L1. TML-High was seen in 11.8% and MSI-High in 1.8% of tumors. Sixty-nine different genes were found mutated with incidences ranging from 0.5% to 54%. PDL-1 expression was seen in 22.1% of tumors. Targetable gene fusions were rare (n=3) but they occurred with significantly lower TML and no instances of microsatellite instability. Using a multiplex testing approach, 28% of CUPs had biomarkers of response to the immune check-point blockade, making CUP one of the most likely indications to benefit from immune checkpoint inhibitors.

Comparison of progression-free survival (PFS) on comprehensive multiplatform profiling-guided therapy to PFS on prior therapy: A pooled analysis from 4 contemporary prospective studies
Poster Display Session
Poster: 1676P, Hall 8
September 11, 1:15 – 2:15 p.m. CEDT

Summary: PFS typically declines with subsequent treatment regimens. However, molecular profiling of tumors to help guide treatment has shown clinical benefit. Data from four independent, physician-led studies included 202 patients whose tissue samples were submitted for comprehensive multiplatform profiling. Clinical benefit was defined as a PFS ratio of =1.3 (PFS of profile-driven therapy / PFS of prior therapy). A median PFS of 120 days was observed with CGP+ directed therapies compared to 89.5 days in prior therapies (HR=0.70, p=0.0120). Seventy-three of evaluable 140 patients had a PFS ratio = 1.3. Over 70% of treated patients received chemotherapy alone, while 21% of patients received targeted therapies, either alone or in combination with chemotherapy or hormone therapy. Contrary to the expected decline in PFS, patients had a better outcome when treated with CGP+ guided treatments. This was driven by the precise use of available chemotherapeutic resources rather than expensive and often inaccessible targeted therapies.

About Caris Life Sciences®
Caris Life Sciences® is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. Caris Molecular Intelligence®, the company's Comprehensive Genomic Profiling Plus (CGP+) molecular testing service and the world's leading immunotherapy diagnostic expert, assesses DNA, RNA and proteins, including microsatellite instability (MSI), total mutational load (TML) and PD-L1, to reveal a molecular blueprint to guide more precise and personalized treatment  decisions.  The ADAPT Biotargeting System, the company's revolutionary and unbiased profiling platform, is currently being utilized for drug target identification, therapeutic discovery and development, fixed tissue-based companion diagnostics, blood-based cancer screening and biomarker identification. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe and other international markets. To learn more, please visit www.CarisLifeSciences.com.

Media Inquiries:
The Ruth Group
Kirsten Thomas / Joanna Zimmerman
Tel: +1-508-280-6592 / +1-646-536-7006
175318@email4pr.com

View original content:http://www.prnewswire.com/news-releases/caris-life-sciences-announces-presentations-at-esmo-2017-highlighting-ability-of-its-tumor-molecular-profiling-to-develop-therapeutic-strategies-300515451.html


'/>"/>
SOURCE Caris Life Sciences
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Caris Life Sciences Non-Invasive Liquid Biopsy Platform ADAPT Biotargeting System Demonstrates Potential to Improve Accuracy of Breast Cancer Diagnosis
2. Caris Life Sciences to Present Research Supporting the Benefit of Precision Medicine in the Diagnosis and Treatment of Breast Cancer at the 2015 San Antonio Breast Cancer Symposium (SABCS)
3. Caris Molecular Intelligence Tumor Profiling Identifies Potential Responders to Anticancer Therapy Across a Range of Tumor Types
4. New Clinical Data Demonstrate Clinical Utility of Caris Molecular Intelligence Profiling to Aid Treatment Selection for Rare or Refractory Solid Tumors
5. Clinical Validity of Molecular Profiling from Caris Life Sciences Confirmed by Study Demonstrating Increased Median Overall Survival and Clinical Impact on Treatment Decisions
6. Caris Life Sciences Designates Fox Chase Cancer Center a Caris Center of Excellence in Precision Medicine
7. Caris Life Sciences Presents New Tumor Profiling Research Providing Insights into the Clinical Benefit of Targeted Therapies for Colorectal Cancer Treatment-Resistant Subgroups
8. Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features
9. Caris Life Sciences Presents Large Cohort Biomarker Analyses that Characterizes Drug Resistances and Pathway Aberrations to Inform Targeted Anticancer Treatment Strategies
10. Caris Life Sciences Designates Virginia Cancer Specialists as a Caris Center of Excellence
11. Caris Life Sciences Designates MedStar Health a Caris Center of Excellence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... 2017  Commended for their devotion to personalized service, SMP ... number one in the South Florida Business Journal,s 50 Fastest-Growing ... yearly list, the national specialty pharmacy has found its niche.  ... will soon be honored by SFBJ as the 2017 Power ... Set to receive his award in October, Bardisa said of ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... Del. (PRWEB) , ... October 12, 2017 , ... ... and advisory services for healthcare compliance program management, will showcase a range of ... National Association for Assisted Living (NCAL) Convention and Expo to be held October ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... a leader in post-acute health care, have expanded their existing home health joint ... Health. , AccentCare has been operating a joint venture home health company with ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards luncheon ... editorial and design excellence across a range of sectors. This year’s program included the ...
Breaking Medicine News(10 mins):